SCHEMBL23368199

SCHEMBL23368199

CC(C)(C)OC(=O)Nc1ccc(Oc2cccc(-c3nnc(C4CC4)o3)c2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP17A1 P05093 1/20 0.39
BRAF P15056 4/20 0.39
LIPG Q9Y5X9 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
KDR P35968 3/20 0.38
TNKS O95271 2/20 0.38
PARP2 Q9UGN5 2/20 0.38
PARP1 P09874 1/20 0.38
TP53 P04637 1/20 0.38
MAPK14 Q16539 1/20 0.38
POLB P06746 1/20 0.37
BACE1 P56817 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30203050 1.00 KDM4E (0.40) KDM4EMAPTALDH1A1CYP17A1BRAF
SCHEMBL23355377 0.87 KDM4E (0.44) KDM4EMAPTALDH1A1TNKSPARP2
SCHEMBL30203277 0.86 CYP17A1 (0.42) KDM4EMAPTALDH1A1CYP17A1BRAF
SCHEMBL23368213 0.86 CYP17A1 (0.42) KDM4EMAPTALDH1A1CYP17A1BRAF
SCHEMBL24926621 0.84 MAPT (0.41) KDM4EMAPTALDH1A1CYP17A1TP53
SCHEMBL30203143 0.84 MAPT (0.41) KDM4EMAPTALDH1A1CYP17A1TP53
SCHEMBL23355402 0.81 KDM4E (0.41) KDM4EMAPTALDH1A1BRAFKDR
SCHEMBL30203040 0.81 BRAF (0.40) MAPTCYP17A1BRAFLIPGKDR
SCHEMBL24926751 0.81 BRAF (0.40) MAPTCYP17A1BRAFLIPGKDR
SCHEMBL24926744 0.76 CYP17A1 (0.41) CYP17A1KDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-01-26 US disclosed
EP-3822263-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-05-19 EP disclosed
CN-112334460-A Biaryl ether type quinazoline derivative 第一三共株式会社 2021-02-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES ERBB2, EGFR, ERBB3 KDM4E 2631/4885MAPT 4074/4885ALDH1A1 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.